Top Tech Companies in Boston, MA (4,742)

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Strong Revenue Growth: Revenue increased from $698.4M in 2023 to $907.0M in 2025 (roughly 14% growth in both 2024 and 2025), with Q1–Q2 2026 up 15% and 13% year over year, respectively. Management guides to 10–13% revenue growth for 2026, indicating continued expansion.

Profitability: GAAP net income and adjusted EBITDA rose sharply in 2025 (+53% and +25%, respectively), and Q2 2026 adjusted EBITDA increased to $84.7M. Operating cash generation was solid in Q2 2026, reinforcing financial stability.

Market Expansion: The paying‑dealer base reached 34,629 in Q2 2026 (+5% YoY) with faster growth internationally (+11% vs. +3% in the U.S.). Monetization per dealer improved as Q2 2026 QARSD rose 7% year over year (U.S. +8%, International +11%).

Strong Revenue Growth: UK company filings indicate revenue rose from about £169.4m in 2023 to £197.0m in 2024, evidencing clear double-digit growth. Parent-company reporting in 2025 also attributed an increase in its ‘Other revenues’ to growth in Simply Business.

Profitability: Operating profit reportedly increased from roughly £24.2m to £45.9m in 2024, rising far faster than revenue. This points to improving margins and efficiency alongside scale.

Market Expansion: The business surpassed one million customers globally in 2024 and later reached one million in the UK, with continued activity in the U.S. and new partnerships and office investments. These milestones suggest ongoing expansion of reach and channels.

Profitability: Operating income has risen materially alongside growth, with the latest quarter reporting meaningful GAAP and adjusted operating profits and expanding margins. This indicates the business is scaling while improving earnings quality.

Resilient & Sustainable Growth: Gross profit is expanding at a strong, accelerating pace, with both Cash App and Square contributing and management raising full‑year outlooks. Longer‑term disclosures also highlight multi‑year compounding in gross profit per user across ecosystems.

Cost & Operational Efficiency: A leaner organizational structure and disciplined spending have driven record adjusted operating margins and improved operating leverage. Efficiency gains appear to be a second engine alongside revenue drivers.

Resilient & Sustainable Growth: Revenue has increased year over year to a new high, with all three major service lines posting gains despite a slower pace. Growth remains uneven by region, but the overall trajectory is upward over the last several fiscal years.

Future-Ready Strategy: Multi‑billion‑dollar investments in technology—especially nearly $1.5B in AI—along with acquisitions and scaling managed services indicate a deliberate pivot to future growth levers. Leadership attention to next‑generation audit and AI‑enabled capabilities underscores preparation for emerging demand.

Strong Market Position & Advantage: The organization is characterized as a leading global professional‑services network with broad scale across assurance, advisory, and tax and repeated external recognitions in select consulting categories. Reach across major multinational clients supports durable competitive positioning.

Strong Market Position & Advantage: Adoption spans 1,300+ biotechnology organizations with usage reported across more than half of the top 50 biopharma companies, signaling durable positioning in life‑sciences R&D software. Multiple sources characterize the platform as a leading life‑sciences R&D cloud used by both startups and major enterprises.

Product Line Growth: The company continues to launch and expand major offerings, including Benchling AI, antibody‑discovery capabilities, automation/analysis tools, and extensions into new scientific workflows such as small‑molecule chemistry. Acquisitions like PipeBio further broaden capability depth in biologics and related R&D domains.

Innovation-Driven Growth: AI is a clear growth vector, with reports that 500 biotech companies used Benchling AI in its first year and the product subsequently reached general availability. Team acquisitions (e.g., ReSync Bio and Sphinx Bio) and partnerships (e.g., with Anthropic) underscore a deliberate push to embed advanced models into scientific workflows.

Strong Revenue Growth: Company updates describe double-digit revenue growth in 2024, back-to-back record years, and roughly 30% year-over-year new-business growth across 2024–2025. Momentum is further indicated by reported acceleration in cloud/SASE/microsegmentation activity.

Customer Loyalty & Retention: Customer net retention of 107% in 2025 suggests expansion within the existing base. This points to durable relationships with large enterprises across multiple industries.

Product Line Growth: The portfolio expanded via the 2024 acquisition of AKIPS and the addition of AI-driven capabilities, extending from policy management into broader network visibility and operations. Growth in cloud, SASE, and microsegmentation (reported at 2.5× in 2025) illustrates traction for newer offerings.

Investor Backing & Capital Strength: Significant financing includes a $56.1M Series C in 2024 and additional growth-capital funding from CIBC Innovation Banking in March 2026, signaling continued investor confidence and runway. Company communications indicate these funds are directed toward product development, R&D, customer success, and sales.

Product Line Growth: Recent launches and expansions span Renewal Analytics, workers’ compensation capabilities (including a claims-triage solution), and a major expansion of the Group Health analytics platform, alongside an integrated Risk Management Life Cycle solution. This pattern points to broadening coverage across underwriting, renewals, and claims.

Customer Loyalty & Retention: Current materials highlight hundreds of enterprise deployments with very high client retention, paired with ongoing wins and deployments in 2025–26 (e.g., Community Health Options, Evolution Risk Partners, and continued 2026 additions). These signals suggest a sticky and expanding customer base.

Strong Revenue Growth: Reported results show revenue rising from $3.67B (2023) to $4.77B (2024) to $6.05B (2025), with early 2026 revenue and guidance pointing to further gains. Q1 2026 continued to grow year over year, alongside expanding sportsbook handle and average monthly payers.

Profitability: Reported results show Adjusted EBITDA improving from $181M (2024) to $620M (2025) and a shift to positive GAAP net income in 2025. Guidance indicates substantial Adjusted EBITDA for 2026.

Product Line Growth: Company disclosures describe rising iGaming revenue in 2025 and the launch of new offerings like Predictions and a consolidated “super app.” These additions broaden the business beyond traditional sportsbook and DFS.

Product Line Growth: Active ETFs are expanding, with MFS entering the U.S. ETF market in late 2024 and generating about $1.2B of net inflows and over $1.4B in AUM by year‑end 2025. The lineup continued to scale in 2026 with additional active ETF launches.

Strong Market Position & Advantage: Scale remains substantial, with AUM around $651.4B at year‑end 2025 and generally in the $640–$660B range through mid‑2026. Company materials also cite a top‑10 standing among U.S. active long‑term mutual fund and ETF managers.

Profitability: Earnings resilience is evident as higher average net assets supported slightly higher earnings and an improved pre‑tax operating margin in Q2 2026. This points to operational strength even amid flow headwinds.

Strong Revenue Growth: Bookings are reported to have grown 103% year over year in 2025, exiting at a roughly $1.1B annualized run rate, indicating rapid top-line momentum. Additional signals such as sustained wholesale growth reinforce that commercial scale is accelerating.

Healthy Cash Flow: Operations are described as cash-flow positive in 2025 while growth accelerated, suggesting improving financial sustainability alongside expansion. This combination points to scaling that is not purely subsidized by burn.

Investor Backing & Capital Strength: A $575M Series G at a $10.1B valuation underscores substantial access to capital and confidence from prominent investors. This financing is framed as enabling continued international expansion and hiring.

Strong Revenue Growth: Revenue grew 26% year over year in FY2024. ARR increased 30% in 2023 after crossing the $100M threshold in 2022.

Profitability: Operations remained profitable and cash‑flow positive in FY2024 while the organization expanded to just under 600 employees.

Investor Backing & Capital Strength: A July 2024 majority investment led by Vista Equity Partners (with TCV and KKR) valued the company at about $1.2B. This reflects substantial external capital support for continued expansion.

Strong Revenue Growth: Available evidence indicates sustained top-line expansion, with company-reported growth corroborated by repeated placements on independent fast-growth lists such as the Inc. 5000 and the Financial Times’ Americas ranking. These signals collectively point to continuing revenue momentum rather than a one-off spike.

Strong Hiring & Retention: Headcount has increased substantially since 2021, with recent statements describing ongoing hiring and acceleration year over year. Active postings across Cloud Engineering, ServiceNow, and related roles further indicate expansion of the workforce.

Market Expansion: The company extended its footprint beyond North America into EMEA and later into APAC, including initial hires in Australia. Growth in delivery activity and practice presence across these regions suggests a broader market reach.

Strong Revenue Growth: Recent filings and earnings updates indicate sustained double-digit increases across annual and quarterly revenue, with momentum continuing into 2026. Guidance was raised during the year, reinforcing ongoing top-line expansion across core verticals.

Profitability: Results point to improving earnings quality, including a shift to positive net income on an annual basis and expanding adjusted EBITDA margins. Management also signaled further margin gains in 2026.

Customer Loyalty & Retention: Disclosures highlight a growing client base alongside net dollar-based retention that indicates expansion within existing customers. Wins across education, travel, healthcare, and B2B suggest durable relationships that support recurring growth.

Strong Revenue Growth: ARR is described as growing over 50% annually for the past three years, and earlier disclosures cite a 522% ARR increase and 407% customer growth over four years. Directional third-party tracking also shows new-customer activity as recently as March 2026.

Profitability: The business is characterized as cash-flow positive and profitable while growing organically without outside financing. This indicates an ability to fund operations and expansion from internal performance.

Customer Loyalty & Retention: Recent case studies describe customers expanding adoption across additional business units and use cases after initial deployment. Such within-account growth signals stickiness among existing customers.

Investor Backing & Capital Strength: Funding reached a $200M Series C in July 2024 at a $1B valuation with prominent investors. Available evidence suggests substantial capital to scale and strong external confidence.

Market Expansion: Engagements extended across governments and enterprises, including the UK’s £8M three-year program, a CBP contract expansion, and new deployments with General Atomics Aeronautical Systems and Scarbrough Global; by 2026, the company said 8 of the world’s 10 largest logistics providers were customers. These signals indicate continued penetration into large, international accounts and public-sector programs.

Product Line Growth: The offering broadened beyond supply-chain mapping into compliance, procurement, trade-risk management, and customs-automation workflows, including the 2026 Cervo AI acquisition. 2025–2026 materials describe additional use cases and live customer deployments.

Strong Revenue Growth: Revenue is reported to have expanded dramatically over a recent three-year period, earning recognition on a leading high-growth list. Feedback suggests this reflects substantial commercial traction rather than growth based solely on financing.

Strong Market Position & Advantage: Customer adoption spans 500+ MedTech companies, including deep penetration among the largest enterprises (e.g., 16 of the top 20). Feedback suggests this breadth and upmarket presence signal durable positioning within its niche.

Investor Backing & Capital Strength: Capital raised has surpassed $160M with a recent late-stage round and a valuation near the unicorn threshold. Feedback suggests this funding base supports continued product expansion, AI initiatives, and go-to-market scale.

Market Expansion: District reach has expanded from 1,000+ around the 2021 acquisition to 1,900+ by early 2026, with coverage across 50+ states and over half of U.S. EL students. This indicates broadening geographic penetration and customer footprint.

Product Line Growth: The offering has evolved from EL program management and instructional tools into a unified ELD platform that now includes benchmark assessment via the 2026 Ellevation Benchmark launch. This broader scope points to increased relevance and potential expansion within existing districts.

Strong Market Position & Advantage: The company is frequently described as a leading, specialized provider in its EL/MLL niche, serving 1,900+ districts and 2.5M+ learners. Such penetration suggests a defensible position within its targeted category.

Profitability: Adjusted EBITDA and margins expanded, with Q2 2026 EBITDA up 30% year over year and margin improving to 37%, alongside higher net income. This pattern indicates operating leverage as earnings outpace the top line.

Strong Revenue Growth: Revenue rose 7% in 2025 and accelerated to 11% year over year in Q2 2026, with multiple sequential quarters showing improving trends. The recent trajectory points to faster growth rather than a flat profile.

Healthy Cash Flow: Free cash flow is guided to grow at more than 30% for 2026 and was later raised to the high-40% range, while Q2 2026 generated $57.4M in operating cash. Debt reduction in 1H 2026, including repayment of $205M in convertibles, further supports balance-sheet strength.

Resilient & Sustainable Growth: Revenue and ARR continued to rise, with ARR surpassing $300M by 2025 and revenue increasing in 2024. Feedback suggests growth has moderated from earlier hypergrowth into a steadier, efficiency‑focused trajectory while the customer base expanded to 4,500+.

Product Line Growth: Snyk Code reached $100M in ARR and newer offerings such as DAST and AI‑focused products (e.g., Evo) showed strong momentum. These developments indicate the platform is extending beyond its original core into additional security categories.

Market Expansion: Enterprise adoption intensified, with that segment driving a large share of new additions and AI security opening fresh routes to demand. Customer counts grew materially from 2024 into 2025, signaling broader market reach.